MedTrace Logo

A Randomised, Double-Blind, Placebo-Controlled Study Assessing the Effect of Fenofibrate, Coenzyme Q10 and Their co-Administration on Ventricular Diastolic Function in Patients With Type 2 Diabetes

NCT00703482 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 278

Last updated 2008-06-25

No results posted yet for this study

Summary

The purpose of this study was to study the effect of different combinations of fenofibrate and coenzyme Q10 on ventricular diastolic function in patients with Type II diabetes

Conditions

  • Patients With Type 2 Diabetes

Interventions

DRUG

Fenofibrate/CoQ10

Fenofibrate pbo/CoQ10 placebo

DRUG

Fenofibrate/CoQ10

Fenofibrate pbo/CoQ10 200 mg

DRUG

Fenofibrate/CoQ10

Fenofibrate 160mg/CoQ10 placebo

DRUG

Fenofibrate/CoQ10

Fenofibrate 80/CoQ10 100 mg

DRUG

Fenofibrate/CoQ10

Fenofibrate 160mg/CoQ10 100 mg

DRUG

Fenofibrate/CoQ10

Fenofibrate 80 /CoQ10 200 mg

DRUG

Fenofibrate/CoQ10

Fenofibrate 160mg/CoQ10 200 mg

Sponsors & Collaborators

  • Solvay Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Global Clinical Director Solvay · Solvay Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-05-31
Primary Completion
2004-09-30
Completion
2004-09-30

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00703482 on ClinicalTrials.gov